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Abstract  
The TTC12-ANKK1-DRD2 gene-cluster has been implicated in adult smoking. Here, we investigated 
the contribution of individual genes in the TTC12-ANKK1-DRD2 cluster in smoking and their 
association with smoking-associated reward processing in adolescence. A meta-analysis of TTC12-
ANKK1-DRD2 variants and self-reported smoking behaviours was performed in four European 
adolescent cohorts (N = 14,084). The minor G-allele of rs2236709, mapping TTC12, was associated 
with self-reported smoking (p = 5.0 × 10 −4) and higher plasma cotinine levels ( p = 7.0 × 10 −5 ). This 
risk allele was linked to an increased ventral-striatal blood-oxygen level dependent (BOLD) response 
during reward anticipation (n = 1,263) and with higher DRD2 gene expression in the striatum (p = 
0.013), but not with TTC12 or ANKK gene expression. These data suggest a role for the TTC12-
ANKK1-DRD2 gene-cluster in adolescent smoking behaviours, provide evidence for the involvement 
of DRD2 in the early stages of addiction and support the notion that genetically driven inter-
individual differences in dopaminergic transmission mediate reward sensitivity and risk to smoking. 
 
Introduction 
Smoking is one of the leading causes of premature death (World Health Organization, 2015). The 
majority of adult smokers (80–90%) initiate smoking during adolescence (Wittchen et al., 2008) and 
genetic factors were found to explain 44% of the individual differences (Vink et al., 2005). 
Adolescence is thus associated with an increased risk of developing long-lasting dependencies to 
nicotine and other substances (Van De Ven et al., 2010), rendering this developmental period critical 
for the investigation of genetic risk factors and the resulting neurobehavioral mechanisms implicated 
in tobacco smoking. However, our knowledge on how genes inﬂuence brain mechanisms in smoking 
is limited, and existing ﬁndings are often based on sample sizes not large enough to yield conclusive 
results (Munafo and Flint, 2011). Moreover, the investigation of smoking in adolescents is often 
hampered by reporting biases resulting from self-report measures (Kandel et al., 2006), thus 
requiring complementation by biologically-veriﬁed markers of nicotine use such as cotinine 
(Keskitalo et al., 2009).  
Smoking in adolescence, in particular smoking initiation, is inﬂuenced by behaviours such as risk 
taking and impulsiveness, which reﬂect dissociation between the development of the subcortical 
reward system and a comparatively delayed maturation of cortical inhibitory functions characteristic 
for this developmental period (Lydon et al., 2014
together with the direct consequence of chronic tobacco exposure, resulting in a neurobehavioral 
context distinct from that in adolescents. This suggests that genetic factors and the biological 
processes mediating smoking behaviour may be different in adolescents and adults. For example in 
adults, it has previously shown that a gene-cluster containing the dopamine receptor 2 (DRD2), the 
ankyrin repeat and kinase domain containing 1 (ANKK1)  and the tetratricopeptide repeat domain 12 
( TTC12)  genes, is associated with tobacco smoking (Ducci et al., 2011; Gelernter et al., 2006). 
Similar results were found in adolescents with associations stronger in adolescence than in mid-
adulthood (Ducci et al., 2011). While this observation supports the notion of shifting biological 
processes underlying tobacco smoking across the life span, the mechanisms by which variations in 
this gene- cluster exert their biological effect on smoking behaviour and smoking initiation in 
adolescents have not yet been elucidated.  
TTC12, ANKK1 and DRD2 are located in close proximity on chromosome 11 in a region of high linkage 
disequilibrium (LD). In addition to nicotine, the gene-cluster has been implicated in alcohol and 
opiate addiction (Nelson et al., 2013; Xu et al., 2004; Yang et al., 2007), suggesting that its inﬂuence 
on smoking may be exerted through a mechanism which is not substance-speciﬁc. TTC12 encodes 
for the tetratricopeptide repeat domain 12 protein, which is implicated in dopaminergic 
transmission and neurodevelopment (Castelo-Branco and Arenas, 2006). ANKK1 is hypothesized to 
encode a signalling protein which mediates the expression of DRD2 (Huang et al., 2009). DRD2 in 
turn has a central role in regulating the dopamine reward system that mediates the reinforcing 
effects of all known addictive sub- stances including nicotine mainly through striatal dopaminergic 
transmission (Sweitzer et al., 2012). While other dopamine-related genes have been associated to 
smoking behaviours (Herman et al., 2014), we were interested in further investigating the role of this 
genetic region in early smoking initiation (Mayhew et al., 2000) and in characterising the molecular 
and neurological mechanisms underlying this association. 
 
Speciﬁcally, we aimed (i) to identify single nucleotide polymorphisms (SNPs) in the TTC12-ANKK1-
DRD2 gene- cluster, associated with self-reported cigarette smoking in adolescents through meta-
analysis of smoking data from 14,084 youths and blood cotinine levels, an objective measure of 
nicotine exposure, in a subset of 2,540 youths,  
(ii) to functionally characterize relevant SNPs by measuring allele-speciﬁc gene expression in human 
post-mortem striatal brain tissue and (iii) to assess the genotype effect on reward sensitivity by 
analysing its relation with the blood-oxygen level-dependent (BOLD) response in the ventral striatum 
during reward anticipation, risk taking and tobacco smoking in a subset of adolescents from the 
IMAGEN sample (Fig. 1). 
Experimental procedures 
Participants 
We included 4512 adolescents from the Northern Fin- land Birth Cohort NFBC1966 (Sabatti et al., 
2009), 4307 from NFBC1986 (Vaarasmaki et al., 2009), 3674 from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) (Golding, 1990), and 1591 (of which 1263 had data on functional 
Magnetic Resonance Imaging (fMRI) data and 1085 on risk taking) from IMAGEN (Schumann et al., 
2010). Demographic characteristics and phenotypic distribution of the samples are reported in Table 
1.   
Smoking-related phenotypes 
Lifetime smoking, measuring the number and occasions of cigarette smoking adapted for 
adolescents who have lesser degree of exposure to smoke than adults, was self reported in each 
cohort (see Supplementary-Material for details in each cohort; Ducci et al., 2011), and recoded into 
four categories: Never-Tried (never smoked), Ever- Tried (smoked at least once), Smokers (smoked 
more than once in the last 30 days), as previously used (Ducci et al., 2011)  and Weekly-Smokers 
(smoked at least once a week in the last month). We used Never-Tried as our reference group to 
contrast with Ever-Tried, and subsequently validated our results by further contrasting with ado- 
lescents who smoke occasionally (Smokers) and regularly (Weekly-Smokers). 
Genetic data 
We chose 33 SNPs based on data availability in the cohort that was genotyped ﬁrst, i.e. NFBC1966. 
Not all of these 33 SNPs were available in each sample. (SNPs and LD structures for each sample can 
be found in Supplementary-Fig. 1, MAF of the separated cohorts can be found in Supplementary 
Table 1). 
Cotinine level 
Plasma cotinine and genotypic data were available in n = 2540 ALSPAC participants (see 
Supplementary-Material). 
Brain genotype and gene expression 
We extracted gene expression levels of TTC12, ANKK1 and DRD2 in the striatum from the GEO series 
GSE25219 database (Kang et al., 2011). Probe clusters assessing expression across the entire 
transcript of TTC12, ANKK1 and DRD2 were extracted (Transcript Cluster IDs 3349453, 3349535 and 
3391653, respectively). We independently replicated the association between DRD2 expression 
levels (Transcript exon probe ID 3391671) and rs2236709 genotypes in 93 post-mortem cortical 
brain tissue samples of European ethnicity, SNPExpress (Heinzen et al., 2008). 
 Functional MRI 
Brain activation during reward anticipation was measured using a modiﬁed monetary incentive delay 
(MID) fMRI task (Knutson et al., 2000) in a sample of 1263 individuals from the IMAGEN sample. 
Gender, recruitment site and handed- ness were included as covariates. Based on previous ﬁndings 
(Yacubian et al., 2006), we focused on the ventral striatum (bilateral) as regions of interest (ROIs) 
(family-wise-error (FWE)-corrected, p < 0.05) as 9-mm spheres from the contrast ‘anticipation of 
large reward > anticipation of no re- ward’ ( ± 15, 9, −9 in Montreal Neurological Institute (MNI) 
space) (see Supplementary-Materials for more details). 
Risk taking 
We used the Cambridge Gambling Task (CGT) from the Cambridge Cognition Neuropsychological 
Test Automated Battery (CANTAB; Cambridge Cognition http://www. cambridgecognition.com/ ). 
Statistical analyses 
Genetic-association analyses and meta-analysis Genetic data analysis used Plink v1.07 ( 
http://pngu.mgh. harvard.edu/ ∼purcell/plink/ ) if not otherwise indicated. Single marker 
association analyses were conducted using logistic or linear regression (for binary or quantitative 
traits, respectively) (see also Supplementary-Materials). Each genotype was coded as the number of 
copies of the minor allele in all cohorts. Analyses controlled for gender, (all samples) age and site 
(IMAGEN).  
Meta-analysis was performed using the meta-analysis procedure from Plink. Signiﬁcant results after 
Bonferroni- correction were investigated further (see also Table 2). 
Association of genotype and BOLD responses in the ventral striatum, brain activation and risk taking 
in the IMAGEN cohort  
We carried forward the results of the conﬁrmatory analysis to investigate associations with brain 
activation and behavioural phenotypes underlying reward processing. ANOVAs comparing extracted 
mean ventral striatum BOLD responses across genotypes for those SNPs showing associations to 
self- reported smoking and cotinine were carried out in SPSS version 20.0 (IBM Corp., Armonk, NY). 
We explored associations of the smoking risk variants within TTC12-ANKK1-DRD2 gene-cluster with 
risk taking. We expected to ﬁnd positive associations between genetic risk for smoking and risk 
taking and tested for this association one-tailed. 
Results 
A summary of the main ﬁndings is illustrated in Fig. 1.   
 
 Fig. 2 Association between 33 single nucleotide polymorphisms (SNPs) covering the chromosome 
11q23 TTC12-ANKK1-DRD2 gene- cluster and self-reported smoking behavior in adolescence. Results 
of the meta-analyses across the NFBC1966, NFBC1986, ALSPAC and IMAGEN cohorts are reported. p 
-values were meta- p -values computed under ﬁxed effect models. Given the multiple testing 
correction for all SNPs a signiﬁcance threshold of 0.0015 was used. The blue diamond indicates the 
most signiﬁcantly associated SNP. This was rs2236709 with p = 5.0 × 10 −4 for Ever-Tried vs. Never-
Tried, rs2236709 with p = 0.001 for Smokers vs. Never-Tried and rs2236709 with p = 0.001 for 
Weekly Smokers vs. Never-Tried.  For other SNPs, diamonds are colored in a white-to-red scale 
corresponding to R2 values from 0 to 1 with the most signiﬁcant SNPs. The SNP position refers to 
National Center for Biotechnology Information build 35. Estimated recombination rates are from 
HapMap and gene annotations are from UCSC genome browser with build. (B) Forest plots for 
rs2236709 for the comparisons of the reference group (i.e. Never-Tried) with Ever-Tried, Smokers 
and Weekly-Smokers.  Box areas are proportional to the weight of the individual study. The overall 
summary odds ratios (OR) computed with a ﬁxed effect model are represented by a diamond whose 
width indicate the 95% conﬁdence interval (CI). Results of the analyses were as follows: Ever-Tried 
vs. Never-Tried OR = 1.10, 95%CI 1.04–1.16, p = 0.5.0 × 10 −4; Smokers vs. Never-Tried OR = 1.13, 
95% CI 1.05–1.22, p = 0.001 and Weekly-Smokers vs. Never-Tried OR = 1.16, 95% CI 1.06–1.27, p = 
0.001 on the left, middle and right forest plots, respectively. (C, left plot) Association between 33 
SNPs and cotinine level in the ALSPAC cohort. Blue diamond indicates the most signiﬁcantly 
associated SNP (rs2236709), as determined by linear regression analyses. Other diamonds are color-
coded in a white-to-orange scale corresponding to increasing R2values of the respective SNP with 
rs2236709. The SNP position refers to National Center for Biotechnology Information build 35. 
Estimated recombination rates are from HapMap and gene annotations are from UCSC genome 
browser with build 35 coordinates. (C, right plot) Mean cotinine level (SE) according to rs2236709 
genotypes (linear regression analysis: β = 0.11, p = 0.5.0 × 10 −4). Mean AA = 6.35, SE = 0.72, n = 
1489; Mean AG = 7.94, SE = 1.18, n = 900; and Mean GG = 19.62, SE = 4.86, n = 151; post-hoc 
comparisons: AA vs. AG, p = 0.843, R2 = 0.0005, AA vs. GG, p = 3.67E-5, R2 = 0.02 and AG vs. GG, p = 
0.001, R2 = 0.013. 
Meta-analysis exploring the association between TTC12-ANKKI-DRD2 and smoking 
Comparing adolescents who Never-Tried smoking with those who Ever-Tried across four cohorts, we 
identiﬁed a significant association with rs2236709 (Risk allele G; Odds ratio (OR) = 1.10, 95% 
conﬁdence interval (CI): 1.04–1.16, p = 5.0 × 10 −4) (Fig. 2 and Table 2). The minor G-allele of 
rs2236709 was linked to increased risk for smoking amongst subgroups of regular smokers (Smokers 
vs. Never-Tried:  OR = 1.13, 95% CI: 1.05–1.22, p = 0.001; Weekly-Smokers 
 
Fig. 3 (A) Expression of DRD2, TTC12 and ANKK1 in the human striatum across the lifetime. The x -
axis represents different stages of fetal and postnatal development, as indicated. PCW = post-
conception weeks, M = months, Y = years. (B) Striatal expression of DRD2 corrected for effects of 
developmental stage and stratiﬁed by rs2236709 genotypes. The dotted line visualizes the linear 
regression against the number of minor G-alleles (n AA = 22, n AG = 16 and, n GG = 5). 
Association of cotinine level and self-reported smoking behavior 
Higher cotinine levels correlated with a higher number of self-reported cigarettes (Spearman’s ρ = 
0.33, p = 3.7 × 10 −53), thus validating self-reported smoking. Mean cotinine levels in ng/ml (SD) for 
each cate- gory of smokers were: Never-Tried = 0.73 (2.73), Ever- Tried = 15.18 (46.51), Smokers = 
28.13 (61.64) and Weekly- Smokers = 64.97 (82.51). One-way ANOVA revealed signiﬁcant difference 
across lifetime smoking categories (F(3,3319) = 25.09, p = 4.80 × 10 −16 , R2  = 0.022). Stratiﬁcation 
of mean plasma cotinine levels according to rs2236709 genotypes indicated a signiﬁcant positive 
association with the minor G-allele [F(2,2537) = 9.64, p = 6.76 × 10 −5 , R2  = 0.003) ( Fig. 2 C, 
Supplementary Table 4), thus conﬁrming the association of rs2236709 with self-reported smoking. 
Rs2236709 inﬂuences on striatal DRD2 expression 
Rs2236709 is located within TTC12 and is in LD with the other genes in the locus, ANKK1 and DRD2 
(see Supplementary-Material Fig. 1). To investigate which of these three genes contributed to the 
effects of rs2236709 on smoking, we analysed their expression in post-mortem human brain 
samples. Fig. 3 A shows expression of TTC12, ANKK1 and DRD2 in the striatum across the lifetime. It 
was indicated that DRD2 mRNA levels in the striatum increased steadily during the foetal stages and 
reached a peak in adolescence, while ANKK1 and TTC12 expression levels were low overall. We 
performed association analyses to investigate the effects of rs2236709 on striatal DRD2, TTC12 and 
ANKK1 expression and included developmental stage as a covariate. The minor G-allele of rs2236709 
was associated with increased expression of DRD2 in the striatum (r = 0.39, p = 0.013, df = 37; Fig. 3 
B). Neither expression of TTC12 nor that of ANKK1 was inﬂuenced by rs2236709 genotypes (p = 
0.176 and p = 0.244, respectively). There was no association of gender (p = 0.627) or RNA integrity ( 
p = 0.296) with DRD2 gene expression.  
As there is, to our knowledge, no other dataset contains expression levels of DRD2 in the striatum 
and rs2236709 genotype data, we independently replicated the association between DRD2 
expression levels and rs2236709 in cortical brain tissue samples of European ethnicity (Heinzen et 
al., 2008), and found the association to be signiﬁcant (p uncorrected = 0.003, p corrected = 0.049, 
corrected for the number of DRD2 probes). 
Association of rs2236709 genotype and ventral striatum BOLD response during reward 
anticipation 
As our results suggest that altered dopaminergic trans- mission in reward related brain areas (e.g., 
the ventral striatum) may underlie the association of rs2236709 with smoking, we further measured 
associations of this variant with BOLD response during reward anticipation in the ventral striatum of 
1236 IMAGEN participants. Due to a skewed allele distribution of rs2236709 (n AA = 706, n AG = 467, 
n GG = 90), we pooled heterozygotes and GG- homozygotes (G-carriers) and compared them to AA-
homozygotes. Our results show a signiﬁcantly higher BOLD response in the left ventral striatum of G-
carriers vs. AA-homozygotes [F(1,1261) = 5.803, p uncorrected = 0.016, p corrected = 0.032, R2  = 
0.005, Supplementary-Materials), indicating an association of the risk allele (G) with greater reward 
sensitivity and increased DRD2 expression. No signiﬁcant associations of rs2236709 genotypes with 
BOLD response in the right ventral striatum (p = 0.237) were observed.  
Association between risk taking, rs2236709, and ventral striatum BOLD response during reward 
anticipation 
As we expected a positive association between genetic risk for smoking and risk taking, this 
association was tested one-tailed. Risk taking positively associated with risk allele (G) of rs2236709 (r 
= 0.056, p = 0.033), and ventral striatal BOLD response (left: r = 0.033, p = 0.112; right: r = 0.049, p = 
0.034). Risk taking also signiﬁcantly associated with the number of occasions of lifetime cigarette 
smoking (r = 0.056, p = 0.034). 
Discussion 
The current study carried out a neurobehavioral characterization of the TTC12- ANKK1- DRD2 gene-
cluster and smoking in adolescence using four large datasets from different European countries. Our 
result demonstrated that this gene- locus exerts its effect on smoking behaviors such as smoking 
initiation and frequency already in the very early stages of nicotine abuse. To attain a mechanistic 
understanding of the associations of the minor G-allele of rs2236709 with both increased self-
reported nicotine intake and higher cotinine levels in adolescents, we found that the genetic risk 
factor rs2236709 regulates DRD2 gene expression, and is also associated with activation of ventral 
striatum during reward anticipation and risk taking, a behaviour associated with drug initiation.  
DRD2 is a key molecular determinant of reward sensitivity (Sweitzer et al., 2012), which reaches its 
peak expression in the striatum during adolescence. High DRD2 expression in- creases sensitivity to 
rewarding stimuli, thus increases sensitivity to the effects of substances (DiNieri et al., 2011) as well 
as risk taking (Cocker et al., 2012). This combination increases vulnerability for addictive behaviors 
(Leyton and Vezina, 2014). Thus, enhanced DRD2 expression in adolescents is likely to be one 
component of risk for substance abuse and smoking in particular. Whereas DRD2 receptor 
availability is reduced during the compulsive stages of sub- stance addiction (Johnson and Kenny, 
2010), early substance use has been linked to increased DRD2 expression levels in the ventral 
striatum (Koob and Volkow, 2009), suggesting a differential regulation of DRD2 in adolescents 
experimenting with drugs compared to established nicotine dependence in adults.  
Our results suggest that carriers of rs2236709 G-risk allele are at a particularly high risk of nicotine 
abuse, presumably due to an allele-speciﬁc increase in DRD2 expression, in carriers of the G-risk 
allele found in human post-mortem brain tissue retrieved from the striatum. While our cohorts have 
different ancestry the LD structure of the rs2236709 locus is similar, suggesting that the ﬁndings in 
the post-mortem human brains can be extended to all our cohorts. Concurrently, increased 
ventrostriatal response during reward anticipation was observed in carriers of the G-risk allele in 
functional neuroimaging analyses of 14 year-old IMAGEN participants. Together these ﬁndings 
suggest an enhanced (ventro-)striatal dopaminergic activity underlying the observed association. 
Our cognitive ﬁndings using the IMAGEN sample are in keeping with this interpretation, namely that 
carriers of the risk allele showed higher risk taking behavior, which in turn was associated with 
increased ventral striatal activation and with increased nicotine use.  
We did not detect signiﬁcant association between smoking frequency and ventral striatal activity in 
this sample of 14 year-old adolescents in which 72% had never smoked. This might be explained by 
insufﬁcient exposure to cigarettes due to young age and/or reduced availability of cigarettes 
compared to older cohorts, such as NFBC1966 where only 32% adolescents had never smoked at 
that age.  
Rs2236709 is localized in the second intron of the TTC12 gene locus and tags a haplotype that ranges 
from the promoter to the third exon of the TTC12 gene. While it is correlated with DRD2 expression 
in the striatum, it is not associated with the expression of TTC12 itself. However, it is well known 
that even Cis -acting gene expression can be regulated by genetic variations that are not 
immediately adjacent to the gene they are regulating (Kirsten et al., 2015).  
This study has some limitations: (i) different cohorts applied different measures to assess smoking 
behaviour, which limited us from obtaining a continuous measure consistent across studies, but 
instead combined information into distinct groups. (ii) Smoking habits have been subject to changing 
societal and legal attitudes over the last decades. Data acquisition among the different cohorts 
spreads over several decades, which was not accounted for. (iii) Cotinine can also account for second 
hand smoking, moreover the half- life of cotinine being 16–18 h is much shorter than some of the 
self-reported smoking behaviours that measure longer tobacco use (Jarvis et al., 1988; Perez-Stable 
et al., 1995; Vartiainen et al., 2002). (iv)Genetic heterogeneity between studies should be noted as 
we pooled all samples of European ancestry due to limited data on adolescent smoking. Two cohorts 
(NFBC1966, NFBC1986) were of Finnish ancestry, and genetically distinct from the other two 
European cohorts (IMAGEN, ALSPAC), which might limit generalization of our ﬁndings. Notably, 
despite some differences of the mi- nor allele frequency (MAF), the direction of the smoking-risk 
SNP effects is consistent across cohorts and I2 of rs2236709 indicated no heterogeneity across 
cohorts.  
Our work proposes a neurobiological pathway to nicotine abuse in a developmental period 
characterized by both vulnerability to the effects of nicotine, and great therapeutic potential to 
prevent or overcome its abuse (Toumbourou et al., 2007). Noting the recent success of interventions 
targeting behavioral risk proﬁles (Conrod et al., 2013), our neurobehavioral characterization 
provided a basis for developing interventions targeting biological mechanisms under- lying nicotine 
abuse. 
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